Biosimilars To Generate $215bn In Savings Through 2026, Says IQVIA
Losses Of Exclusivity For Major Products To Offset Biopharma Growth
Executive Summary
Biosimilar competition, spurred on by significant losses of exclusivity for major products like Humira, Stelara and Xarelto, will lead to significant cost savings for healthcare systems and patients over the next five years according to a recent report from IQVIA. While these entrants are set to limit growth in the branded pharmaceuticals space, innovation is set to continue driving global spending.